MX375421B - Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular. - Google Patents

Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.

Info

Publication number
MX375421B
MX375421B MX2016001719A MX2016001719A MX375421B MX 375421 B MX375421 B MX 375421B MX 2016001719 A MX2016001719 A MX 2016001719A MX 2016001719 A MX2016001719 A MX 2016001719A MX 375421 B MX375421 B MX 375421B
Authority
MX
Mexico
Prior art keywords
event
predicting
risk
equipment
methods
Prior art date
Application number
MX2016001719A
Other languages
English (en)
Other versions
MX2016001719A (es
Inventor
Amir Boufenzer
Hafid Ait-Oufella
Marc Derive
Nicolas Danchin
Sébastien Gibot
Tabasomme Simon
Original Assignee
Inotrem
Aphp Assist Publique Hopitaux De Paris
Inst Nat Sante Rech Med
Univ De Lorraine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotrem, Aphp Assist Publique Hopitaux De Paris, Inst Nat Sante Rech Med, Univ De Lorraine filed Critical Inotrem
Publication of MX2016001719A publication Critical patent/MX2016001719A/es
Publication of MX375421B publication Critical patent/MX375421B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)

Abstract

La presente invención se refiere a un método para diagnosticar un evento o enfermedad cardiovascular en un individuo al medir el nivel de sTREM-1 en una muestra.
MX2016001719A 2013-08-09 2014-08-08 Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular. MX375421B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361863987P 2013-08-09 2013-08-09
EP14153519.5A EP2835641A1 (en) 2013-08-09 2014-01-31 Methods and kits for predicting the risk of having a cardiovascular disease or event
PCT/EP2014/067120 WO2015018936A1 (en) 2013-08-09 2014-08-08 Methods and kits for predicting the risk of having a cardiovascular disease or event

Publications (2)

Publication Number Publication Date
MX2016001719A MX2016001719A (es) 2016-06-02
MX375421B true MX375421B (es) 2025-03-06

Family

ID=50030127

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001719A MX375421B (es) 2013-08-09 2014-08-08 Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.

Country Status (15)

Country Link
US (1) US10948498B2 (es)
EP (2) EP2835641A1 (es)
JP (1) JP6562915B2 (es)
KR (1) KR102266302B1 (es)
CN (1) CN105765382B (es)
AU (1) AU2014304421B2 (es)
BR (1) BR112016002668B1 (es)
CA (1) CA2920652C (es)
ES (1) ES2973810T3 (es)
IL (1) IL244013B (es)
MX (1) MX375421B (es)
NZ (1) NZ716643A (es)
RU (1) RU2721690C2 (es)
WO (1) WO2015018936A1 (es)
ZA (1) ZA201600963B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106053831A (zh) * 2016-06-05 2016-10-26 潘时辉 一种用于自身免疫病检测的试剂盒
FI127416B (en) * 2016-09-29 2018-05-31 Oy Medix Biochemica Ab Cardiovascular risk assessment method
US20210364532A1 (en) 2018-09-28 2021-11-25 Inotrem Use of soluble trem-1 levels for identifying subjects susceptible to respond to an anti-inflammatory therapy
KR102257830B1 (ko) * 2018-12-18 2021-05-28 연세대학교 산학협력단 사망 위험도의 예측 방법 및 이를 이용한 디바이스
JP7712913B2 (ja) * 2019-09-03 2025-07-24 ソマロジック オペレーティング カンパニー インコーポレイテッド 心血管リスク／イベントの予測及びその使用
US20230016187A1 (en) * 2019-11-25 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Trem-1 inhibitors for the treatment of vaso-occlusions and tissue injuries in patients suffering from sickle cell disease
CN116507915A (zh) * 2020-06-05 2023-07-28 伊诺特伦公司 可溶性trem-1作为患有冠状病毒感染的受试者的严重程度或并发症的标志物
CA3181469A1 (en) * 2020-06-05 2021-12-09 Jean-Jacques GARAUD Soluble trem-1 as a marker of severity or complications for a subject suffering from a coronavirus infection
WO2022119327A1 (ko) 2020-12-02 2022-06-09 (주)지놈오피니언 선천적 대사질환 위험도 점수를 이용한 심뇌혈관질환의 위험도 측정 방법
US20240173376A1 (en) 2021-03-12 2024-05-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Trem-1 inhibitors for the treatment of marfan syndrome
EP4416501A1 (en) 2021-10-11 2024-08-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of trem-1 for predicting and preventing postoperative complications after cardiac surgery with cardiopulmonary by-pass
WO2025196177A1 (en) 2024-03-21 2025-09-25 Institut National de la Santé et de la Recherche Médicale Use of soluble trem-1 as a biomarker for assessing the risk of cardiovascular disease in asymptomatic subjects

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084082A1 (en) 1997-03-07 2006-04-20 Human Genome Sciences, Inc. 186 human secreted proteins
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
GB0401730D0 (en) * 2004-01-27 2004-03-03 Bioxell Spa Diagnosis method
EP2121750A2 (en) * 2007-01-16 2009-11-25 Wyeth Inflammation treatment, detection and monitoring via trem-1
EP2174131A1 (en) * 2007-07-23 2010-04-14 Bioxell S.p.a. Screening, therapy and diagnosis
JP2014505259A (ja) * 2011-02-03 2014-02-27 アボット・ラボラトリーズ 慢性心不全における予後診断および診断の方法
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
JP6411218B2 (ja) 2012-02-15 2018-10-24 ノヴォ ノルディスク アー／エス 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体

Also Published As

Publication number Publication date
AU2014304421A1 (en) 2016-02-25
CN105765382B (zh) 2019-09-13
RU2016107954A (ru) 2017-09-14
AU2014304421B2 (en) 2020-01-16
IL244013B (en) 2020-01-30
EP3030901A1 (en) 2016-06-15
KR20160046828A (ko) 2016-04-29
EP3030901C0 (en) 2024-01-10
EP2835641A1 (en) 2015-02-11
JP6562915B2 (ja) 2019-08-21
RU2721690C2 (ru) 2020-05-21
CA2920652C (en) 2023-03-07
MX2016001719A (es) 2016-06-02
JP2016527519A (ja) 2016-09-08
CN105765382A (zh) 2016-07-13
US20160187352A1 (en) 2016-06-30
NZ716643A (en) 2020-06-26
US10948498B2 (en) 2021-03-16
KR102266302B1 (ko) 2021-06-18
ES2973810T3 (es) 2024-06-24
EP3030901B1 (en) 2024-01-10
WO2015018936A1 (en) 2015-02-12
CA2920652A1 (en) 2015-02-12
BR112016002668B1 (pt) 2023-12-12
BR112016002668A2 (pt) 2018-01-30
IL244013A0 (en) 2016-04-21
ZA201600963B (en) 2020-05-27

Similar Documents

Publication Publication Date Title
MX375421B (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
IL264770B (en) Diagnostic assays and kits for detection of folate receptor 1
BR112017009159A2 (pt) métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
MX355416B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
EP3411720C0 (en) METHODS OF DIAGNOSIS AND PROGNOSIS OF CARDIOVASCULAR DISEASES AND EVENTS
BR112014031365A2 (pt) métodos de detectar doenças ou condições
DK2981803T3 (da) Træthedstestning af en testprøve
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
UY36223A (es) Dispositivos para ensayos, métodos para realizar ensayos, kits para ensayos y método para fabricar dispositivos para ensayos
CL2017001212A1 (es) Composiciones, dispositivos y método para pruebas de sensibilidad de síndrome del intestino irritable
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
TR201903974T4 (tr) Tasnif makinesi için otomatik kusur tanı metodu ve cihazı.
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
MX2015010174A (es) Herramientas de diagnostico para predecir la presentacion de preeclampsia.
BR112015030537A2 (pt) método para avaliar planos de estratégia de produção
BR112013026599A2 (pt) conjunto de bobinas contínuas, dispositivo de teste com conjunto de bobinas contínuas e método de teste
MX383423B (es) Método in vitro para el diagnóstico del síndrqme del intestino irritable y la enfermedad inflamatoria intestinal.
BR112017006419A2 (pt) medições cinéticas de tau
MX2016006165A (es) Composiciones y metodos para valorar la funcion intestinal.
CO2018007621A2 (es) Composiciones y métodos para evaluar el riesgo de ocurrencia de cáncer
FI20135183L (fi) Näytelevy ja analysointimenetelmä
AR100013A1 (es) Procedimiento para el monitoreo, cuantificación y evaluación de actividades de pastoreo y rumia realizadas por rumiantes y dispositivo para ejecutarlo
EP2812698A4 (en) BY DOUBLE ACCEPTOR TIME RELEASED FRET
CY1121790T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick

Legal Events

Date Code Title Description
FG Grant or registration